Sinotau Pharmaceutical Group, a leading enterprise in targeted radionuclide theranostics, recently announced completion for a new round of financing over RMB1.1?billion.

This round of financing was invested by many national organizations, industry groups and well-known investment institutions, including SDIC Venture Capital, Goldstone, China Structural Reform Fund, Genertec Venture Capital, CITIC Securities, etc. China Life Private Equity and Lotus Lake Ventures continue to increase their shareholdings.
?
The funds raised in this round will be used for the research, development and clinical application of diagnostic and therapeutic radiopharmaceuticals to bring health benefits to Chinese patients. The successful completion of this round of financing fully reflects the high recognition of Sinotau’s innovative strength and market value by capital and industry.
?
Sinotau is an innovative pharmaceutical company?specializing in the R&D, production, clinical application and academic promotion of radiopharmaceuticals. Headquartered in Beijing,?Sinotau?has?modern radiopharmaceutical R&D centers and production sites?in Shanghai, Jiangsu, Guangdong and Sichuan, and has a branch office in the US,?partnering with more than a dozen or so?multinational pharmaceutical companies.
?
Relying on the world’s leading R&D resources of radiopharmaceutical?precision diagnosis and therapies, Sinotau has taken the lead in a number of radiopharmaceuticals?for?targeted therapies?and precise?diagnostics in the fields of oncology, neurology and cardiology, and has accumulated rich experience in radiopharmaceutical R&D, clinical trials, registration and filing, production and marketing?in China. It is expected that within this year, its Aβ-PET imaging agent for Alzheimer’s disease diagnosis will be approved and marketed in China, which, together with various targeted therapeutic drugs, will provide patients with integrated solutions for precise diagnosis and treatment, helping patients to achieve early diagnosis and treatment, and a lifetime without or delayed onset of disease.